Lebanese Dermatological Society
Belarusian Society of Dermatovenereologists and Cosmetologists
North American Clinical Dermatologic Society
The Dermatologic & Aesthetic Surgery International League
African Association for Dermatology
May/June 2015 • Volume 13 • Issue 3
SKINmed Industry update Jo-Ann Kalaka-Adams, Section Editor
Leading the Way to Healthy Skin in Partnership With Healthcare Professionals Jo-Ann Kalaka-Adams
T
odd Zavodnick was recently appointed President & General Manager of Galderma Laboratories, L.P., a global leader committed to dermatology and skin health.
Fully owned by Nestlé since 2014, Galderma is the operating company of Nestlé Skin Health, a newly created division of the food and wellness giant. Nestlé Skin Health is a worldwide leader focused on helping people improve their life by delivering science-based solutions for the health of skin, hair, and nails. Dating back to 1961, Galderma is present in 80 countries with an extensive product portfolio to treat a range of dermatologic conditions. Skin health needs have never been greater and so are the global growth ambitions of Galderma, for which the United States plays a key role. “Galderma’s single focus on skin health distinguishes it in the marketplace and positions the company to substantially increase its share of the dermatology and aesthetic medicine markets,” Todd Zavodnick stated. “Galderma stands out, because we are not only committed to helping patients with skin conditions but also to helping people with healthy skin to stay well. While the pharmaceutical world concentrates on sick care, Galderma expands its scope to health care, as well.” Under Zavodnick’s leadership, Galderma will accelerate the launching of innovative medical products in the U.S. to improve the quality of life for people of all ages, from birth to retirement. Galderma’s products are designed to treat as well as nourish, heal, protect, and aesthetically enhance the skin. “Our global goal is to grow the number of people we serve worldwide to more than a billion within 10 years,” says Zavodnick. “We put patients and healthcare practitioners at the heart of everything we do.” SKINmed. 2015;13:1–4
Todd Zavodnick.
Zavodnick is proud that U.S. Dermatologists, according to IMS Health databases for 2015, ranked the Galderma Sales Force first in Overall Performance for the 5th consecutive year. “It confirms the value our sales team brings to physicians and their teams and our ongoing commitment to partner with them,” heScan says.this QR
1
code with your © 2015 Pulse Marketing & Communications, QRLLC reader
May/June 2015
SKINmed Industry update
Todd Zavodnick.
The new President spent the last 10 years leading Alcon, and then Galderma Laboratories, in Asia, Europe, the Middle East, Africa, and Latin America. He holds a Bachelor’s Degree in Pharmacy from Rutgers University and an MBA in International Business from the University of Texas in Dallas. Zavodnick resides with his wife and two children in Southlake, Texas.
23 ongoing Phase 4 studies involve nearly 7000 patients in 15 countries. The company also filed 55 new patents. Galderma’s research and development is conducted at its Centers of Excellence at Sophia Antipolis, France, the largest skin research facility in the world; Uppsala, Sweden, the birthplace of NASHA technology and dedicated to research in Aesthetics; and Egerkingen, Switzerland, which is dedicated to innovative therapeutic skincare.
Galderma’s North American headquarters is located in the Dallas-Fort Worth area. Many new talents have recently joined Galderma in North Texas and across the nation in field-based positions. “Galderma’s unique vision for skin health, passionate people, and rich pipeline from a longstanding commitment to science make it a magnet in the industry,” Zavodnick says. “People are key to the success of Galderma and we want Galderma to be recognized as the best place to be.”
Galderma’s Big Three As Galderma’s largest market, North America is a cornerstone of the company’s global activity. Galderma recently aligned its North American affiliate structure to support the company’s global strategy of three specific business units: prescription medications, self-medication products, and aesthetic and corrective solutions. Safia Rizvi is Vice President and General Manager of the U.S. Prescription Business Unit and Miles Harrison is Vice President and General Manager for the U.S. Self-Medication Business. Kelly Huang has just been appointed Vice President and General Manager for Galderma’s Aesthetic and Corrective Business Unit.
Research a Key Priority The company has started to expand its market share by launching multiple new products. Cetaphil® Baby is a dermatologist-tested, over-the-counter line formulated specially for delicate skin, with organic calendula, almond oil, and sunflower oil. Soolantra® Cream is a prescription product for rosacea. Restylane® Silk was recently approved by the FDA for lip enhancement and for the treatment of lines around the mouth in patients over the age of 21. It is the first hyaluronic acid filler to receive FDA approval specifically for lip lines “With the goal to bring highly differentiated treatments and skin solutions to market, we continue to innovate and will launch many new products over the next 18 months,” says Zavodnick.
Prescriptions Galderma’s Prescription Business Unit focuses on pharmaceutical products promoted almost exclusively to health care professionals. Prescription drugs are the heritage of Galderma, with thousands of patents and many of the world’s most prescribed drugs in dermatology including Epiduo® Gel, Differin® Gel, and Oracea® Capsules.
Galderma makes tremendous investments to discover and develop new products and to access ground-breaking technologies. In 2014, the company’s 700 researchers conducted 78 clinical studies with nearly 5000 subjects at 275 sites in 14 countries. Its SKINmed. 2015;13:1–4
Galderma currently offers products to treat skin diseases such as acne, rosacea, eczema, psoriasis, and melasma. Antibiotic-free Epiduo® Gel is the most prescribed topical brand of acne treat-
2
Leading the Way to Healthy Skin
May/June 2015
SKINmed Industry update
ment in the world. In addition, Galderma offers a comprehensive portfolio of rosacea treatments comprising three products with distinctive delivery modes and indications: topical Mirvaso® Gel for persistent facial erythema; systemic Oracea® Capsules, the only oral rosacea treatment approved by FDA; and Soolantra® Cream, a once-daily, antibiotic-free product FDA-approved for the treatment of inflammatory lesions, or bumps and pimples, of rosacea.
Aesthetic & Corrective The Aesthetic & Corrective Business Unit (Box 2) comprises a broad portfolio of products and services for minimally invasive aesthetic treatments. In May 2014 Galderma acquired the rights to distribute Restylane®, Perlane®, Sculptra®, and Dysport® in the U.S. and Canada.
On June 2, Galderma representatives attended the White House National Summit on Antibiotic Stewardship. The invitation was directly related to Galderma’s support of Antibiotic Stewardship and further showcases the company’s leadership in this important initiative (Box 1).
BOX 2 Galderma’s Driving force in Aesthetic & Corrective Research • State-of-the-art expertise in understanding, characterization, and modification of hyaluronic acid and expertise in toxin • 1,000 people worldwide • 80 dedicated researchers in Uppsala, Sweden
BOX 1 Galderma’s support of Antibiotic Stewardship in Dermatology
• 10 R&D projects
• Partnering with the Centers for Disease Control and Prevention’s (CDC) Get Smart About Antibiotics Week in 2014.
• 7 global brands and 18 years of clinical experience with Restylane • 20 million Restylane treatments received by patients globally in 2014
• Taking steps to stop commercialization of topical antibiotics through its national subsidiaries worldwide.
• Restylane as the only international HA filler approved in China.
• Making safe and effective acne treatment alternatives to antibiotics. • Bringing new antibiotic-free treatment options to market.
Restylane® Silk is the first hyaluronic acid filler to receive FDA approval specifically for lip lines. The debut of Restylane® Silk has been extremely successful with already 10% market share in the filler category.
Dr. Phil Brown, Galderma’s Senior Vice President of Medical and Regulatory Affairs, attended the Summit. “This is a great moment for Galderma and we hope to see very exciting things happening on the policy front,” he says.
The aesthetic division counts 200 employees in production. The manufacturing site in Uppsala, Sweden has the capacity to produce up to 10 million units annually. The site is ISO 14001, ISO 13485 and OHSAS 18001 certified and approved for delivery worldwide.
Self-Medication
In April Galderma launched the ASPIRE® Galderma Rewards Program in the U.S. that rewards healthcare providers and patients for their consistent use of and treatment with Galderma’s aesthetic products. Based on connections between healthcare professionals, consumers, and Galderma, the program provides benefit via its online tools and apps, educational content, instant savings and rebates, consumer treatment certificates, and other exclusive rewards.
The company’s Self-Medication Business Unit includes non-prescription, and over-the-counter brands. These products include the power brand Cetaphil® cleansers and moisturizers and the recently launched Benzac® Acne Solutions, Galderma’s first overthe-counter acne formulation. In the spring Galderma was the first pharmaceutical company to launch an Instagram two-week series, “The Benzacs,” to create awareness of mild to moderate acne among teenagers. SKINmed. 2015;13:1–4
3
Leading the Way to Healthy Skin
May/June 2015
SKINmed Industry update
From left to right: Quintin Cassady, Vice President & General Counsel, Legal; Chuck Paschke, Senior Director Organizational Health; Virginie Naigeon, Director, Corporate Communications; Miles Harrison, Vice President & General Manager, Self-Medication Business Unit; Safia Rizvi, Vice President & General Manage, Prescription Business Unit; Todd Zavodnick, President and General Manager, Galderma U.S.; Kelly Huang, Vice President & General Manager, Aesthetic & Corrective Business Unit; Phil Brown, Senior Vice President, Medical and Regulatory Affairs; Han Jansen, Vice President, Finance & Information Technologies; Jake DeBoever, Senior Director & Chief Compliance Officer; Mike Voigt, Vice President, Human Resources & Learning and Development.
Products Available Globally
Galderma Cares
“With our Skin Health vision, Galderma stands out in the industry landscape today,” says Zavodnick. “We have the right people, a broad range of effective and safe skin solutions, and the unique capabilities in R&D and manufacturing of a worldwide leader. What really makes our vision for the future contagious is our genuine passion to drive innovation, partner with healthcare professionals, and bring superior outcomes to patients.”
Since 2012, Galderma has partnered with Camp Wonder and the Children Skin Diseases Foundation. Camp Wonder is a summer camp for children with severe or rare skin diseases. Every year, nearly 100 children with severe and devastating skin diseases enjoy a week away from stares or bullies. Instead, they experience the childhood joys of summer camp. It is a week in which kids get to be kids and friends are made for a lifetime. Camp Wonder is free of charge to the campers and supported by dedicated volunteers and a staff of physicians and nurses.
Galderma has 34 wholly owned affiliates with a worldwide network of distributors in 80 countries and over 5,700 employees. Many products, such as Cetaphil®, the #1 dermatologist-recommended brand of cleansers and moisturizers, are trusted household names. Galderma’s prescription and aesthetic and corrective medical solutions are regularly prescribed by dermatologists, plastic surgeons, pediatricians, family practice physicians, and other health professionals.
SKINmed. 2015;13:1–4
Galderma’s commitment to Camp Wonder includes a generous grant, employee volunteers, and Cetaphil® products during the camp and throughout the year to help support children’s skin health needs. In 2015, Camp Wonder celebrated its 15th anniversary and more than $500,000 has been donated over the last three years. To learn more visit cetaphil.com/campwonder or CSDF.org.
4
Leading the Way to Healthy Skin